Commonwealth of Pennsylvania Public School Empls Retrmt SYS Raises Holdings in Hologic, Inc. $HOLX

Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 54,654 shares of the medical equipment provider’s stock after acquiring an additional 3,339 shares during the quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS’s holdings in Hologic were worth $3,561,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC grew its position in Hologic by 473.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,701,820 shares of the medical equipment provider’s stock worth $111,180,000 after purchasing an additional 1,405,085 shares during the last quarter. Nuance Investments LLC grew its holdings in shares of Hologic by 623.7% during the first quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider’s stock valued at $66,794,000 after buying an additional 931,920 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Hologic by 18.8% during the first quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider’s stock valued at $298,655,000 after buying an additional 764,573 shares during the last quarter. Nuveen LLC purchased a new position in Hologic in the 1st quarter worth $30,317,000. Finally, Sound Shore Management Inc. CT grew its stake in Hologic by 42.6% during the 1st quarter. Sound Shore Management Inc. CT now owns 1,383,628 shares of the medical equipment provider’s stock valued at $85,467,000 after purchasing an additional 413,403 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Stock Performance

NASDAQ:HOLX opened at $74.17 on Thursday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. The company has a fifty day moving average of $70.24 and a two-hundred day moving average of $66.10. The stock has a market capitalization of $16.50 billion, a PE ratio of 30.78, a P/E/G ratio of 2.54 and a beta of 0.65. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $80.31.

Hologic (NASDAQ:HOLX) last released its earnings results on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, topping analysts’ consensus estimates of $1.10 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.05 billion during the quarter, compared to analysts’ expectations of $1.03 billion. During the same quarter in the previous year, the company earned $1.01 earnings per share. The company’s quarterly revenue was up 6.2% on a year-over-year basis. As a group, research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on HOLX shares. Raymond James Financial lowered shares of Hologic from a “moderate buy” rating to a “hold” rating in a research report on Wednesday, October 22nd. Morgan Stanley raised their target price on shares of Hologic from $69.00 to $76.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $78.00 price target on shares of Hologic in a report on Wednesday, October 22nd. Leerink Partners increased their price target on Hologic from $70.00 to $78.00 and gave the stock a “market perform” rating in a research report on Tuesday, October 21st. Finally, Stephens cut Hologic from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $78.00 to $76.00 in a report on Wednesday, October 22nd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and thirteen have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $79.77.

Insider Activity at Hologic

In other news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer directly owned 1,234,624 shares of the company’s stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Christiana Stamoulis sold 7,402 shares of the stock in a transaction on Monday, October 20th. The shares were sold at an average price of $73.07, for a total value of $540,864.14. Following the completion of the transaction, the director directly owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. This represents a 13.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.88% of the company’s stock.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.